Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: Effect on small airways in poorly controlled asthma

Journal of Asthma

Volumn 42, Issue 4, 2005, Pages 257-263

  Thongngarm, Torpong ^a   Silkoff, Philip E ^a   Kossack, William S ^a   Nelson, Harold S ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Airway inflammation; Asthma; HFA beclomethasone; Propellant; Small airways

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; FLUTICASONE; FLUTICASONE PROPIONATE; MONTELUKAST; NORFLURANE; SALBUTAMOL; THEOPHYLLINE; ZAFIRLUKAST;

ADULT; AEROSOL; AIRWAY DYNAMICS; ALCOHOL CONSUMPTION; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; MALE; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE BREATH NITROGEN TEST; SMALL AIRWAY DISEASE; SPIROMETRY; STEROID THERAPY; SUSPENSION; UNSTABLE ANGINA PECTORIS; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADULT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BECLOMETHASONE; BRONCHI; BRONCHODILATOR AGENTS; CHLOROFLUOROCARBONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; MIDDLE AGED; PHARMACEUTICAL SOLUTIONS; PULMONARY VENTILATION; SINGLE-BLIND METHOD; SUSPENSIONS;

EID: 22044435423     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.1081/JAS-200057888     Document Type: Article

References (21)

1. National Heart Lung and Blood Institute of the National Institutes of Health. Guidelines for the Diagnosis and Management of Asthma, Expert Panel Report 2; NIH Publication No. 97-4051. Bethesda, MD: NIH, NHLBI, 1997.
2. Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, Hogg JC. Inflammation of small airways in asthma? J Allergy Clin Immunol 1997; 100:44-51.
3. Kraft M. The distal airways: are they important in asthma? Eur Respir J 1999; 14:1403-1417.
4. Newman SP. A comparison of lung deposition patterns between different asthma inhalers. J Aerosol Med 1995; 8(suppl 3):S21-S26, discussion S27.
5. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002; 122:510-516.
6. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001; 323:253-256.
7. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987; 136:225-244.
8. Gold W. Pulmonary function testing. In: Murray JF, Nadal JA, Mason RJ, Boushey HA Jr, eds. Textbook of Respiratory Medicine. Philadelphia, PA: WB Saunders Co., 2000.
9. SAS, SAS/STAT User's Guide Vol. 8. Gary, NC: SAS Institue, Inc., 1999.
10. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161:9-16.
11. Fairfax A, Hall I, Spelman R. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. Ann Allergy Asthma Immunol 2001; 86:575-582.
12. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane- 134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest 1999; 115:343-351.
13. Magnussen H. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir Med 2000; 94:549-555.
14. Worth H, Muir JF, Pieters WR. Comparison of hydrofluoroalkane- beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control. Respiration 2001; 68:517-526.
15. Reichel W, Dahl R, Ringdal N, Zetterstrom O, van den Elshout FJ, Laitinen LA. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma. Int J Clin Pract 2001; 55:100-106.
16. Goldin JG, Tashkin DP, Kleerup EC, Greaser LE, Haywood UM, Sayre JW, Simmons MD, Suttorp M, Colice GL, Vanden Burgt JA, Aberle DR. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999; 104:258-267.
17. Kraft M, Martin RJ, Wilson S, Djukanovic R, Holgate ST. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999; 159:228-234.
18. Wagner EM, Bleecker ER, Permutt S, Liu MC. Direct assessment of small airways reactivity in human subjects. Am J Respir Crit Care Med 1998; 157:447-452.
19. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J, Macklem PT. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298:1277-1281.
20. Wright JL, Lawson LM, Pare PD, Kennedy S, Wiggs B, Hogg JC. The detection of small airways disease. Am Rev Respir Dis 1984; 129:989-994.
21. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, Donnell D, Hannon S, Colice GL. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104:1215-1222.